Milestone Scientific's preliminary Q2 revenue rises  on base business expansion

Milestone Scientific

01/07/2026 13:42

Overview
US drug delivery device maker's preliminary Q2 revenue rose 21% yr/yr to $2.8 mln
Medical segment revenue expected to rise 300% yr/yr in Q2, driven by international orders and base business expansion

Outlook
Company expects medical segment momentum to accelerate in Q3 2026
Milestone Scientific anticipates more meaningful revenue contributions later in 2026
Company plans to secure dental registrations in Japan, Mexico, Turkey, and India in coming quarters

Result Drivers
BASE BUSINESS EXPANSION - Co said core business performed well, contributing about $2.4 mln in Q2 revenue
INTERNATIONAL ORDERS - About $500,000 in Q2 revenue attributed to international orders, reflecting global demand for technology
MEDICAL SEGMENT GROWTH - Medical segment revenue expected to rise 300% yr/yr in Q2, with progress on reimbursement claims

Company press release: ID:nGNXbWk5T3

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Preliminary  Q2 Revenue
Beat
$2.80 mln
$2.50 mln (2 Analysts)

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Milestone Scientific Inc is $1.00, about 211.5% above its June 30 closing price of $0.32

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)